The city of Boston, Massachusetts, currently has 482 active clinical trials seeking participants for Cancer research studies.
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Recruiting
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery. The specific names of the interventions that will be used are: Y-90 (a type of radiation microsphere bead) Durvalumab (a type of immunotherapy) Gemcitabine (a type of chemotherapy) Cisplatin (a type of chemotherapy)
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Metastatic Intrahepatic Cholangiocarcinoma
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
Recruiting
The purpose of this research study is to learn more about the inherited risk for developing lung cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Lung Cancer, Genetic Disease, Genetic Predisposition, Hereditary Diseases
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Recruiting
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/15/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Esophageal Cancer, Ovarian Cancer, Endometrial Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Non-small Cell Lung (NSCLC), Urothelial Cancer
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
Recruiting
Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might he... Read More
Gender:
Male
Ages:
Between 55 years and 69 years
Trial Updated:
02/13/2024
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts
Conditions: Prostate Cancer
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Recruiting
This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label. The names of the study drugs involved in this study are: Leuprolide (type of ADT) Relugolix (type of ADT)
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Prostate Cancer, Prostatic Neoplasms
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Recruiting
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/10/2024
Locations: Massachusetts General Hospital., Boston, Massachusetts
Conditions: Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Recruiting
This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung
Virtual Health Insurance Navigation Pilot Program for Childhood Survivors (HINTII)
Recruiting
The investigators are conducting a Type I hybrid effectiveness-implementation trial to assess the effectiveness of HINT-S (synchronous) compared to enhanced usual care (EUC) in promoting health insurance literacy, thus reducing worry, unmet health care needs, and financial consequences due to medical costs to improve care and long-term outcomes of childhood cancer survivors. The investigators will also compare HINT-S to HINT-A (asynchronous), a prerecorded, asynchronous version of the 5 HINT-S n... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Childhood Cancer Survivors
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Recruiting
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Strength After Breast Cancer
Recruiting
The goal of this study is to explore whether a group exercise program called Strength After Breast Cancer can be delivered in an outpatient physical therapy clinic to improve physical function among women after treatment for breast cancer. The main questions this study aims to answer are: Can the Strength After Breast Cancer program and the associated outcome battery be successfully delivered in an outpatient physical therapy clinic at Massachusetts General Hospital and do participants find th... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: MGH Institute of Health Professions, Boston, Massachusetts
Conditions: Breast Cancer
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
Recruiting
This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.
Gender:
Male
Ages:
55 years and above
Trial Updated:
02/05/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Hypogonadism, Male, Cancer, Fatigue